Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David A Reardon

Showing results (31-40 of 404) with videos related to

Pageof 41
Sort By:
Biologics : Targets & Therapy|August 27, 2009
Current available therapies and future directions in the treatment of malignant gliomasAnnick Desjardins, David A Reardon, James J Vredenburgh
Expert Review of Anticancer Therapy|April 26, 2017
Angiogenesis inhibitors in tackling recurrent glioblastomaThomas Hundsberger, David A Reardon, Patrick Y Wen
Neurologic Clinics|October 30, 2007
Diagnosis and treatment of high-grade astrocytomaSith Sathornsumetee, Jeremy N Rich, David A Reardon
Discovery Medicine|December 27, 2017
Immunotherapy for glioblastoma: on the sidelines or in the game?David A Reardon, Kai Wucherpfennig, E Antonio Chiocca
CNS Oncology|March 12, 2019
Efficacy and safety of immune checkpoint blockade for brain metastasesMaya Harary, David A Reardon, J Bryan Iorgulescu
American Society of Clinical Oncology Educational Book. American Society of Clinical Oncology. Annual Meeting|May 30, 2013
Antiangiogenic therapy for glioblastoma: the challenge of translating response rate into efficacyJohn de Groot, David A Reardon, Tracy T Batchelor
Expert Review of Anticancer Therapy|May 12, 2007
Antitenascin-C monoclonal antibody radioimmunotherapy for malignant glioma patientsDavid A Reardon, Michael R Zalutsky, Darell D Bigner
Expert Opinion on Investigational Drugs|December 11, 2013
Current status of antiangiogenic therapies for glioblastomasIsabel Arrillaga-Romany, David A Reardon, Patrick Y Wen
Neuro-Oncology|October 25, 2014
Targeted molecular therapies against epidermal growth factor receptor: past experiences and challengesDavid A Reardon, Patrick Y Wen, Ingo K Mellinghoff
Cancer|June 22, 2010
Dose-dense temozolomide regimens: antitumor activity, toxicity, and immunomodulatory effectsBart Neyns, Alicia Tosoni, Wen-Jen Hwu, et al.
Pageof 41

Showing results (31-40 of 404) with videos related to

Sort By:
Pageof 41
Biologics : Targets & Therapy|August 27, 2009
Current available therapies and future directions in the treatment of malignant gliomasAnnick Desjardins, David A Reardon, James J Vredenburgh
Expert Review of Anticancer Therapy|April 26, 2017
Angiogenesis inhibitors in tackling recurrent glioblastomaThomas Hundsberger, David A Reardon, Patrick Y Wen
Neurologic Clinics|October 30, 2007
Diagnosis and treatment of high-grade astrocytomaSith Sathornsumetee, Jeremy N Rich, David A Reardon
Discovery Medicine|December 27, 2017
Immunotherapy for glioblastoma: on the sidelines or in the game?David A Reardon, Kai Wucherpfennig, E Antonio Chiocca
CNS Oncology|March 12, 2019
Efficacy and safety of immune checkpoint blockade for brain metastasesMaya Harary, David A Reardon, J Bryan Iorgulescu
American Society of Clinical Oncology Educational Book. American Society of Clinical Oncology. Annual Meeting|May 30, 2013
Antiangiogenic therapy for glioblastoma: the challenge of translating response rate into efficacyJohn de Groot, David A Reardon, Tracy T Batchelor
Expert Review of Anticancer Therapy|May 12, 2007
Antitenascin-C monoclonal antibody radioimmunotherapy for malignant glioma patientsDavid A Reardon, Michael R Zalutsky, Darell D Bigner
Expert Opinion on Investigational Drugs|December 11, 2013
Current status of antiangiogenic therapies for glioblastomasIsabel Arrillaga-Romany, David A Reardon, Patrick Y Wen
Neuro-Oncology|October 25, 2014
Targeted molecular therapies against epidermal growth factor receptor: past experiences and challengesDavid A Reardon, Patrick Y Wen, Ingo K Mellinghoff
Cancer|June 22, 2010
Dose-dense temozolomide regimens: antitumor activity, toxicity, and immunomodulatory effectsBart Neyns, Alicia Tosoni, Wen-Jen Hwu, et al.
Pageof 41